Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

30.06 -1.07 (-3.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novocure Ltd Ord Sh

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks. 
Via Benzinga
Why NovoCure Stock Was Winning Big This Week
Via The Motley Fool
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds
The company is soon to seek regulatory approval in the U.S. and abroad. 
Via Investor's Business Daily
Navigating 5 Analyst Ratings For NovoCure
Via Benzinga
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Via Benzinga
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. 
Via Benzinga
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Zai Lab
Via Business Wire
Why NovoCure Stock Dived by 13% This Week
Investors found the announced changes to the company's C-suite unsettling. 
Via The Motley Fool
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Novocure
Via Business Wire
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
From Novocure
Via Business Wire
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
From Novocure
Via Business Wire
NovoCure (NVCR) Q3 2024 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Novocure Appoints Christoph Brackmann as Chief Financial Officer
From Novocure
Via Business Wire
Novocure Reports Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session. 
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non-small cell lung cancer patients, demonstrating significant... 
Via Benzinga
Exposures Product Safety
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
The company could have a long path ahead to reimbursement and, ultimately, sales. 
Via Investor's Business Daily
Exposures Product Safety
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novocure to Report Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
From Novocure
Via Business Wire
Novocure Announces Planned CEO Transition
From Novocure
Via Business Wire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.